The clinical research of multi-modality assessment-based strategies for intravenous thrombolysis in acute mild ischemic stroke patients
10.19845/j.cnki.zfysjjbzz.2022.0173
- VernacularTitle:多模式评估在急性轻型缺血性卒中静脉溶栓治疗中的临床研究
- Author:
Runnan LI
1
;
Chunyan HAN
1
;
Qi FANG
1
Author Information
1. Department of Neurology,Dushu Lake Hospital Affiliated to Soochow University,Suzhou 215000,China
- Publication Type:Journal Article
- Keywords:
Mild stroke;
Intravenous thrombolysis;
Prognosis;
Multi-modality assessment-based strategy;
Risk scores
- From:
Journal of Apoplexy and Nervous Diseases
2022;39(8):681-688
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of intravenous thrombolysis in acute mild ischemic stroke patients (National Institution of Health Stroke Scale≤5),moreover,to verify the effectiveness of multi-modality assessment in screening high-risk patients.Methods We retrospectively included 227 patients identified with acute mild neurological deficits treated with or without intravenous thrombolysis.Odds ratios (OR) with their confidence intervals (CI) for different outcomes between groups were assessed by using multivariable binary logistic regression analyses.And the heterogeneity of treatment effect magnitude for excellent outcome［modified Rankin scale (mRS) 0~1 was estimated in different subgroups stratified by optimal cut-off value from receiver operating characteristic curve.Results In multivariate analysis,intravenous thrombolysis could both achieve higher rate of excellent outcome(OR=3.302，95%CI1.488~7.326，P=0.003) and 7 day significant improvement (OR=2.566，95%CI1.287~5.118，P=0.007).However,there was no significant difference in the risk of early neurological deterioration,intracranial hemorrhage transformation or the 90 day stroke recurrence(P>0.05).It is indicated from the subgroup analysis that,compared with non-thrombolytic group,the classification of large artery atherosclerosis(OR=9.448，95%CI1.129~79.035，P=0.038) and baseline ABCD-2 score of 5 or more(OR=2.664，95%CI1.150~6.168，P=0.022) might benefit more from intravenous thrombolysis.Conclusion For acute mild ischemic stroke patients,we reassured the safety and especially the efficacy of intravenous thrombolysis at 7 days and 90 days.Patients with ABCD-2 score of 5 or more and classification of large artery atherosclerosis might benefit more from intravenous thrombolytic therapy.
- Full text:2024072322290225068The clinical research of multi-modality assessment-based strategies for intravenous thrombolysis in acute mild ischemic stroke patients.pdf
